Enhancing clinical evidence by proactively building quality into clinical trials
Open Access
- 20 April 2016
- journal article
- research article
- Published by SAGE Publications in Clinical Trials
- Vol. 13 (4), 439-444
- https://doi.org/10.1177/1740774516643491
Abstract
Background: Stakeholders across the clinical trial enterprise have expressed concern that the current clinical trial enterprise is unsustainable. The cost and complexity of trials have continued to increase, threatening our ability to generate reliable evidence essential for making appropriate decisions concerning the benefits and harms associated with clinical interventions. Overcoming this inefficiency rests on improving protocol design, trial planning, and quality oversight. Methods: The Clinical Trials Transformation Initiative convened a project to evaluate methods to prospectively build quality into the scientific and operational design of clinical trials (“quality-by-design”), such that trials are feasible to conduct and important errors are prevented rather than remediated. A working group evaluated aspects of trial design and oversight and developed the Clinical Trials Transformation Initiative quality-by-design principles document, outlining a series of factors generally relevant to the reliability of trial conclusions and to patient safety. These principles were then applied and further refined during a series of hands-on workshops to evaluate their utility in facilitating proactive, cross-functional dialogue, and decision-making about trial design and planning. Following these workshops, independent qualitative interviews were conducted with 19 workshop attendees to explore the potential challenges for implementing a quality-by-design approach to clinical trials. The Clinical Trials Transformation Initiative project team subsequently developed recommendations and an online resource guide to support implementation of this approach. Conclusion: The Clinical Trials Transformation Initiative quality-by-design principles provide a framework for assuring that clinical trials adequately safeguard participants and provide reliable information on which to make decisions on the effects of treatments. The quality-by-design workshops highlighted the value of active discussions incorporating the different perspectives within and external to an organization (e.g. clinical investigators, research site staff, and trial participants) in improving trial design. Workshop participants also recognized the value of focusing oversight on those aspects of the trial where errors would have a major impact on participant safety and reliability of results. Applying the Clinical Trials Transformation Initiative quality-by-design recommendations and principles should enable organizations to prioritize the most critical determinants of a trial’s quality, identify non-essential activities that can be eliminated to streamline trial conduct and oversight, and formulate appropriate plans to define, avoid, mitigate, monitor, and address important errors.Keywords
This publication has 11 references indexed in Scilit:
- Effects of Extended-Release Niacin with Laropiprant in High-Risk PatientsNew England Journal of Medicine, 2014
- The Imperative of Overcoming Barriers to the Conduct of Large, Simple TrialsJAMA, 2014
- Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012JAMA, 2014
- Clinical Trials: Rethinking How We Ensure QualityDrug Information Journal, 2012
- Monitoring the quality of conduct of clinical trials: a survey of current practicesClinical Trials, 2011
- Sensible approaches for reducing clinical trial costsClinical Trials, 2008
- Ensuring trial validity by data quality assurance and diversification of monitoring methodsClinical Trials, 2008
- Effect of intravenous corticosteroids on death within 14 days in 10 008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trialThe Lancet, 2004
- Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trialsThe Lancet, 2001
- Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial InfarctionNew England Journal of Medicine, 1989